Molecular scanning of the human PPARα gene: Association of the L162V mutation with hyperapobetalipoproteinemia

Journal of Lipid Research

Volumn 41, Issue 6, 2000, Pages 945-952

  Vohl, Marie Claude ^a   Lepage, Pierre ^a   Gaudet, Daniel ^c   Brewer, Carl G ^a   Bétard, Christine ^a   Perron, Patrice ^c   Houde, Ghislaine ^c   Cellier, Christine ^a   Faith, Janet M ^a   Després, Jean Pierre ^b   Morgan, Kenneth ^a,d   Hudson, Thomas J ^a,d,e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Department of Pediatrics and Clinical Research Unit   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Apolipoprotein B; Genetics; Hyperapobetalipoproteinemia; L162V mutation; PPAR ; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HYPERLIPOPROTEINEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ANIMALS; APOLIPOPROTEINS B; BASE SEQUENCE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIAS; MALE; MICE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0033922356     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Schoonjans, K., G. Martin, B. Staels, and J. Auwerx. 1997. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8: 159-166.
2. Schoonjans, K., B. Staels, and J. Auwerx. 1996. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta. 1302: 93-109.
3. Schoonjans, K., B. Staels, and J. Auwerx. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925.
4. Vidal-Puig, A. J., R. V. Considine, M. Jimenez-Linan, A. Werman, W. J. Pories, J. F. Caro, and J. S. Flier. 1997. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99: 2416-2422.
5. Brun, R. P., P. Tontonoz, B. M. Forman, R. Ellis, J. Chen, R. M. Evans, and B. M. Spiegelman. 1996. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10: 974-984.
6. Isseman, I., and S. Green. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347: 645-650.
7. Auboeuf, D., J. Rieusset, L. Fajas, P. Vallier, V. Frering, J. P. Riou, B. Staels, J. Auwerx, M. Laville, and H. Vidal. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46: 1319-1327.
8. Kliewer, S. A., S. S. Sundseth, S. A. Jones, P. J. Brown, G. B. Wisely, C. S. Koble, P. Devchand, W. Wahli, T. M. Willson, J. M. Lenhard, and J. M. Lehmann. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA. 94: 4318-4323.
9. Torra, I. P., P. Gervois, and B. Staels. 1999. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 10: 151-159.
10. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98: 2088-2093.
11. Horrobin, D. F. 1995. Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: a common link between risk factors and coronary and peripheral vascular disease? Prostaglandins Leukot. Essent. Fatty Acids. 53: 385-396.
12. Reaven, G. M. 1994. Syndrome X: 6 years later. J. Intern. Med. Suppl. 736: 13-22.
13. Gaudet, D., S. Arsenault, C. Bélanger, T. Hudson, P. Perron, M. Bernard, and P. Hamet. 1999. Procedure to protect confidentiality of familial data in community genetics and genomic research. Clin. Genet. 55: 259-264.
14. Report on the Expert Committee on the diagnosis and classification of diabetes mellitus. 1997. Diabetes Care. 20: 1183-1197.
15. Couture, P., M. C. Vohl, C. Gagné, D. Gaudet, A. I., Torres, P. J. Lupien, J. P. Després, F. Labrie, J. Simard, and S. Moorjani. 1997. Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French-Canadians. Hum. Mutat. Suppl. 1: s226-s231.
16. Ma, Y., C. Bétard, M. Roy, J. Davignon, and A. Kessling. 1989. Identification of a second "French Canadian" LDL receptor gene deletion and development of a rapid method to detect both deletions. Clinical Genetics. 36: 219-228.
17. Vohl, M. C., P. Couture, S. Moorjani, A. L. Torres, C. Gagne, J. P. Després, P. J. Lupien, F. Labile, and J. Simard. 1995. Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians. Hum. Mutat. 6: 243-246.
18. Standardization of anthropometric measurements. 1998. In The Airlie (VA) Consensus Conference. T. Lohman, A. Roche, and R. Martorel, editors. Human Kinetics Publishers, Champaign, IL. 39-80.
19. Burnstein, K. L., D. L. Bellingham, C. M. Jewell, F. E. Powell-Olivier, and J. A. Cidlowski. 1991. Antoregulation of glucocorticoid receptor gene expression. Steroids. 56: 52-58.
20. McNamara, J. R., and E. J. Schaefer. 1987. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin. Chim. Acta. 166: 1-8.
21. + precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin. Chem. 28: 1379-1387.
22. Friedewald, W. T., R. I. Levy, and D. S. Frederickson. 1972. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
23. Laurell, C. B. 1966. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal. Biochem. 15: 42-52.
24. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1354.
25. Burstein, M., and J. Samaille. 1960. Sur un dosage rapide du cholesterol lié aux alpha et aux bêta lipoprotéines du sérum. Clin. Chem. Acta. 5: 609.
26. Gidez, L. I., G. J. Miller, M. Burnstein, S. Slagle, and H. A. Eder. 1982. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J. Lipid Res. 23: 1206-1223.
27. Moorjani, S., A. Dupont, F. Labrie, P. J. Lupien, D. Brun, C. Gagné, M. Giguère, and A. Bélanger. 1987. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 36: 244-250.
28. Sher, T., H. F. Yi, O. W. McBride, and F. J. Gonzalez. 1993. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochem. 32: 5598-5604.
29. Sham, P. C., and D. Curtis. 1995. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59: 97-105.
30. Gearing, K. L., A. Crickmore, and J. A. Gustafsson. 1994. Structure of the mouse peroxisome proliferator activated receptor alpha gene. Biochem. Biophys. Res. Commun. 199: 255-263.
31. Tugwood, J. D., T. C. Aldridge, K. G. Lambe, N. Macdonald, and M. J. Woodyatt. 1996. Peroxisome proliferator-activated receptors: structures and function. Ann. NY Acad. Sci. 804: 252-265.
32. Holden, P. R., and J. D. Tugwood. 1999. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 22: 1-8.
33. Castelli, W. P., R. J. Garrison, P. W. F. Wilson, R. D. Abbot, S. Kalousdian, and W. B. Kannel. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. J. Am. Med. Assoc. 256: 2835-2838.
34. Castelli, W. P., K. Anderson, P. W. Wilson, and D. Levy. 1992. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol. 2: 23-28.
35. Lamarche, B., A. Tchernof, P. Mauriège, B. Cantin, G. R. Dagenais, P. J. Lupien, and J. P. Després. 1998. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. J. Am. Med. Assoc. 279: 1955-1961.
36. Bolibar, I., S. G. Thompson, A. von Eckardstein, M. Sandkamp, and G. Assmann. 1995. Dose-response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group. Arterioscler. Thromb. Vasc. Biol. 15: 1035-1042.
37. Lamarche, B., S. Moorjani, P. J. Lupien, R. Cantin, P. M. Bernard, G. R. Dagenais, and J. P. Després. 1996. Apolipoprotein A-I and B levels ant the risk of ischemic heart disease during five-year follow-up of men in the Québec Cardiovascular Study. Circulation. 94: 273-278.
38. Sniderman, A., B. G. Brown, B. F. Stewart, and K. Cianflone. 1992. From familial combined hyperlipidemia to hyperapoB: unravelling the overproduction of hepatic apolipoprotein B. Curr. Opin. Lipidol. 3: 137-142.
39. Després, J. P. 1998. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes. Res. 6 Suppl. 1: 8S-17S.
40. Djouadi, F., C. J. Weinheimer, J. E. Saffitz, C. Pitchford, J. Bastin, F. J. Gonzalez, and D. P. Kelly. 1998. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J. Clin. Invest. 102: 1083-1091.
41. Peters, J. M., N. Hennuyer, B. Staels, J. C. Fruchart, C. Fievet, F. J. Gonzalez, and J. Auwerx. 1997. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J. Biol. Chem. 272: 27307-27312.
42. Lamb, R. G., J. C. Koch, and S. R. Bush. 1993. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion. Biochim. Biophys. Acta. 1165: 299-305.
43. Ruotolo, G., C. G. Ericsson, C. Tettamanti, F. Karpe, L. Grip, B. Svane, J. Nilsson, U. de Faire, and A. Hamsten. 1998. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J. Am. Coll. Cardiol. 32: 1648-1656.
44. Ericsson, C. G. 1998. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Eur. Heart J. 19 Suppl H: H37-H41.
45. de Faire, U., C. G. Ericsson, L. Grip, J. Nilsson, B. Svane, and A. Hamsten. 1997. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials. Cardiovasc. Drugs Ther. 11 Suppl 1: 257-263.
46. Miller, D. B., and J. D. Spence. 1998. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34: 155-162.
47. Davignon, J. 1994. Fibrates: a review of important issues and recent findings. Can. J. Cardiol. 10: 61B.
48. Bell, A. R., R. Savory, N. J. Horley, A. I. Choudhury, M. Dickins, T. J. Gray, A. M. Salter, and D. R. Bell. 1998. Molecular basis of non-responsiveness to peroxisome proliferators: the guinea-pig PPARalpha is functional and mediates peroxisome proliferator-induced hypolipidaemia. Biochem. J. 332: 689-693.
49. Heyer, E., and M. Tremblay. 1995. Variability of the genetic contribution of Quebec population founders associated to some deleterious genes. Am. J. Hum. Genet. 56: 970-978.
50. De Braekeleer, M., F. Giasson, J. Mathieu, M. Roy, J. P. Bouchard, and K. Morgan. 1993. Genetic epidemiology of autosomal recessive spastic ataxia of Charlevoix-Saguenay in northeastern Quebec. Genet. Epidemiol. 10: 17-25.
51. De Braekeleer, M., C. Dionne, C. Gagné, P. Julien, D. Brun, M. R. Ven Murthy, and P. J. Lupien. 1991. Founder effect in familial hyperchylotmicronemia among French Canadians of Quebec. Hum. Hered. 41: 168-173.
52. Vohl, M. C., S. Moorjani, M. Roy, D. Gaudet, A. L. Torres, A. Minnich, C. Gagné, G. Tremblay, M. Lambert, J. Bergeron, P. Couture, P. Perron, S. Blaichman, L. D. Brun, J. Davignon, P. J. Lupien, and J. P. Després. 1997. Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. Clin. Genet. 52: 1-6.
53. Bergeron, J., T. Normand, A. Bharucha, M. R. Ven Murthy, P. Julien, C. Gagné, C. Dionne, M. De Braekeleer, D. Brun, and M. R. Hayden. 1992. Prevalence, geographical distribution and genealogical investigations of mutation 188 of lipoprotein lipase gene in the French Canadian population of Quebec. Clin. Genet. 41: 206-210.
54. Murthy, V., P. Julien, and C. Gagné. 1996. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol. Ther. 70: 101-135.